Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CytoMed Therapeutics Limited (GDTC : NSDQ)

• Company Description    CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. CytoMed Therapeutics Limited is based in SINGAPORE. Number of Employees: 43

• Price / Volume Information    Yesterday's Closing Price: $2.20 Daily Weekly Monthly 20 Day Moving Average: 6,265 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: -0.36 52 Week High: $4.05 52 Week Low: $1.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.04% -0.81% 12 Week -10.57% -24.78% Year To Date -35.29% -39.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 08-22 ONE COMMONWEALTH 1 COMMONWEALTH LANE - SINGAPORE,U0 149544 SGP ph: 65-6250-7738 fax: - None http://www.cytomed.sg

• General Corporate Information    Officers CHOO Chee Kong - Chairman GOH Yvonne - Chief Financial Officer Mark LEONG Kei Wei - Director ZENG Jieming - Director LOH Yuin Han - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: Y1R80M106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: -0.36 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.64 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 9.89 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 9.89 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -3,628.72 Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 0.61 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.05 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 4.42

Powered by Zacks Investment Research ©